Stock SRDX SURMODICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Surmodics, Inc.

Equities

SRDX

US8688731004

Medical Equipment, Supplies & Distribution

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
26.17 USD 0.00% Intraday chart for Surmodics, Inc. -1.21% -28.01%
Feb. 06 Barrington Trims Price Target on SurModics to $70 From $71, Keeps Outperform Rating MT
Feb. 01 Needham Adjusts SurModics' Price Target to $47 From $44, Maintains Buy Rating MT

Valuation

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 617.1 531.1 771.3 425.8 453.6 372.6 - -
Enterprise Value (EV) 1 617.1 531.1 771.3 425.8 453.6 372.6 372.6 372.6
P/E ratio 83.2 x 486 x 185 x -15.5 x -292 x -22.4 x 65.4 x -
Yield - - - - - - - -
Capitalization / Revenue 6.17 x 5.6 x 7.34 x 4.26 x 3.42 x 3.11 x 2.74 x 2.41 x
EV / Revenue 6.17 x 5.6 x 7.34 x 4.26 x 3.42 x 3.11 x 2.74 x 2.41 x
EV / EBITDA 43.7 x 92.1 x 64.2 x -33.1 x 32.7 x 88.1 x 26.2 x 17.1 x
EV / FCF 302 x 51.4 x 76.3 x -20.7 x 59.7 x -18.8 x 22.3 x 13.9 x
FCF Yield 0.33% 1.95% 1.31% -4.84% 1.67% -5.31% 4.48% 7.17%
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 13,491 13,650 13,872 14,005 14,134 14,236 - -
Reference price 2 45.74 38.91 55.60 30.40 32.09 26.17 26.17 26.17
Announcement Date 10/31/19 11/4/20 11/10/21 11/9/22 11/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 100.1 94.86 105.1 99.95 132.6 119.7 136.2 154.7
EBITDA 1 14.13 5.765 12.02 -12.85 13.87 4.23 14.21 21.82
EBIT 1 6.469 -1.251 6.703 -22.1 5.603 -12.43 6.928 2.667
Operating Margin 6.46% -1.32% 6.38% -22.11% 4.23% -10.38% 5.09% 1.72%
Earnings before Tax (EBT) 1 7.558 -1.454 6.346 -22.49 2.487 -15.61 5.713 -0.208
Net income 1 7.592 1.123 4.237 -27.27 -1.536 -16.08 5.574 0.113
Net margin 7.59% 1.18% 4.03% -27.29% -1.16% -13.43% 4.09% 0.07%
EPS 2 0.5500 0.0800 0.3000 -1.960 -0.1100 -1.170 0.4000 -
Free Cash Flow 1 2.04 10.34 10.11 -20.59 7.596 -19.78 16.68 26.73
FCF margin 2.04% 10.9% 9.62% -20.6% 5.73% -16.53% 12.25% 17.28%
FCF Conversion (EBITDA) 14.44% 179.34% 84.1% - 54.75% - 117.42% 122.5%
FCF Conversion (Net income) 26.87% 920.66% 238.61% - - - 299.26% 23,651.33%
Dividend per Share - - - - - - - -
Announcement Date 10/31/19 11/4/20 11/10/21 11/9/22 11/8/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: September 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2
Net sales 1 23.97 23 26.11 24.85 25.99 24.93 27.2 52.48 27.97 30.55 28.84 29.88 30.4 33.54 34.1
EBITDA 1 -1.04 -1.032 -2.578 -4.852 -4.39 -5.232 -3.284 23.5 -0.283 1.966 0.0303 0.0247 0.1973 3.469 5.255
EBIT 1 -0.489 -3.441 -4.9 -7.143 -6.613 -7.229 -5.301 21.41 -2.45 -0.322 -4.362 -3.9 -3.852 0.142 1.328
Operating Margin -2.04% -14.96% -18.77% -28.74% -25.45% -28.99% -19.49% 40.8% -8.76% -1.05% -15.12% -13.05% -12.67% 0.42% 3.89%
Earnings before Tax (EBT) 1 -0.562 -3.518 -5.002 -7.181 -6.792 -8.008 -7.365 20.65 -2.789 -0.724 -5.262 -4.838 -4.802 -0.218 0.9925
Net income 1 -0.289 -2.812 -4.083 -5.651 -14.73 -7.843 -7.733 7.346 6.694 -0.786 -5.714 -4.859 -4.714 -0.077 1.01
Net margin -1.21% -12.22% -15.64% -22.74% -56.67% -31.46% -28.43% 14% 23.93% -2.57% -19.81% -16.26% -15.51% -0.23% 2.96%
EPS 2 -0.0200 -0.2000 -0.2900 -0.4100 -1.060 -0.5600 -0.5500 0.5200 0.4700 -0.0600 -0.3950 -0.3650 -0.3600 -0.005000 0.0750
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/10/21 2/3/22 4/27/22 7/27/22 11/9/22 2/6/23 4/26/23 8/2/23 11/8/23 2/1/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: September 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow 1 2.04 10.3 10.1 -20.6 7.6 -19.8 16.7 26.7
ROE (net income / shareholders' equity) - 0.89% 3.13% -22% - -14.1% 7.7% -
ROA (Net income/ Total Assets) - - - -15.5% - -10.6% 6.8% -
Assets 1 - - - 176.5 - 151.7 81.97 -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 6 3.67 5.28 3.37 2.92 4.72 4.75 6
Capex / Sales 5.99% 3.87% 5.02% 3.37% 2.2% 3.94% 3.49% 3.88%
Announcement Date 10/31/19 11/4/20 11/10/21 11/9/22 11/8/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Surmodics, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
26.17 USD
Average target price
59 USD
Spread / Average Target
+125.45%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Medical Equipment, Supplies & Distribution

1st Jan change Capi.
SURMODICS, INC. Stock Surmodics, Inc.
-28.01% 373M
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
Other Medical Equipment, Supplies & Distribution
  1. Stock Market
  2. Equities
  3. SRDX Stock
  4. Financials Surmodics, Inc.